This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.
Participants aged between 18 and 75 years at enrollment.
Participants with compensated cirrhosis due to MASH, confirmed by non-invasive assessments.
Participants with history or presence of at least two components of metabolic syndrome.
Participants with other chronic liver diseases.
Participants with evidence or history of decompensated liver disease or hepatocellular carcinoma.
Participants with history of Type 1 diabetes mellitus or major Type 2 diabetes complications.
Participants with history or evidence of chronic pancreatic disease; pancreatic injury or acute pancreatitis within 6 months before screening.